Market Overview:
The global montelukast drug market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of asthma and allergic rhinitis, rising awareness about asthma and its treatment, and growing demand for generic drugs. By type, the market is segmented into tablets and oral granules. The tablets segment is expected to account for a larger share of the market than oral granules during the forecast period. By application, the hospital segment is expected to account for a larger share of the market than drug stores during the forecast period.
Product Definition:
Montelukast is a leukotriene receptor antagonist used in the treatment of asthma and allergic rhinitis. It is also used to prevent exercise-induced bronchoconstriction.
Tablets:
Tablets are small flat pieces of paper or plastic used as a drug delivery system. They can be consumed orally and are available in different forms such as film, strip, and liquid-filled. The Montelukast drug is packaged in tablet form which is the most widely used type of tablets across the globe.
Oral Granules:
Oral granules are used for the treatment of respiratory disorders such as asthma. It is also used to reduce inflammation and pain in case of dental caries, periodontal disease, gingivitis and stomatitis. Montelukast drug market is expected to witness significant growth over the forecast period owing to its increasing application areas coupled with rising awareness about its benefits among patients suffering from chronic respiratory diseases such as asthma or COPD.
Application Insights:
The others segment held the largest share of more than 70.0% in 2017. The segment includes asthma and allergic rhinitis drugs market, which is expected to witness significant growth on account of increasing awareness about allergies among the population globally.
As per a WHO study, prevalence of asthma was found to be highest in Eastern Asia (Oceania) with around 17% as compared to Europe (8%) and North America (11%). Prevalence is higher among urban as well as rural areas in this region which indicates that access to healthcare facilities along with effective treatment for asthma may not be adequate enough for all patients suffering from this disease across the Oceania region.
Regional Analysis:
North America dominated the global montelukast drug market in 2017. This is attributed to growing awareness about various asthma management options, increasing prevalence of asthma and other factors. Moreover, a well-established healthcare infrastructure and high disposable income are some of the major drivers for this region.
Asia Pacific is expected to be one of the fastest-growing regions over the forecast period owing to rising product demand as a result of increased awareness about its therapeutic benefits among patients suffering from asthma attacks & related symptoms such as shortness of breath, wheezing, coughing etc., along with its generic version availability at affordable prices in countries like India & China aftermarketing approval by FDA and EMEA regulatory authorities for treating adult asthmatic patients (18 years old above) with moderate severity (BTS 4 or 5).
Growth Factors:
- Increasing prevalence of asthma and other respiratory diseases
- Growing awareness about the benefits of montelukast drug therapy
- Rising demand for generic drugs due to their lower cost
- Technological advancements in the field of respiratory medicine
- Growing number of mergers and acquisitions among pharmaceutical companies
Scope Of The Report
Report Attributes
Report Details
Report Title
Montelukast Drug Market Research Report
By Type
Tablets, Oral Granules
By Application
Hospital, Drug Store, Others
By Companies
Merck & Co., Teva, Mylan, Glenmark Pharmaceuticals, Hikma Group, Sandoz, Torrent Pharmaceuticals, Lannett Company, Apotex, Dr. Reddys Laboratories, Aurobindo Pharma, Accord Healthcare, Hetero, Unimark, Ajanta Pharma, MACLEODS, Jubilant Pharma, Unichem Laboratories, Amneal Pharmaceuticals, Shanghai Anbison Lab, Perrigo, Cipla, CSPC Ouyi Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Montelukast Drug Market Report Segments:
The global Montelukast Drug market is segmented on the basis of:
Types
Tablets, Oral Granules
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drug Store, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co.
- Teva
- Mylan
- Glenmark Pharmaceuticals
- Hikma Group
- Sandoz
- Torrent Pharmaceuticals
- Lannett Company
- Apotex
- Dr. Reddys Laboratories
- Aurobindo Pharma
- Accord Healthcare
- Hetero
- Unimark
- Ajanta Pharma
- MACLEODS
- Jubilant Pharma
- Unichem Laboratories
- Amneal Pharmaceuticals
- Shanghai Anbison Lab
- Perrigo
- Cipla
- CSPC Ouyi Pharmaceutical
Highlights of The Montelukast Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tablets
- Oral Granules
- By Application:
- Hospital
- Drug Store
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Montelukast Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Montelukast is a medication used to treat asthma. It works by reducing the inflammation and swelling in the airways.
Some of the key players operating in the montelukast drug market are Merck & Co., Teva, Mylan, Glenmark Pharmaceuticals, Hikma Group, Sandoz, Torrent Pharmaceuticals, Lannett Company, Apotex, Dr. Reddys Laboratories, Aurobindo Pharma, Accord Healthcare, Hetero, Unimark, Ajanta Pharma, MACLEODS, Jubilant Pharma, Unichem Laboratories, Amneal Pharmaceuticals, Shanghai Anbison Lab, Perrigo, Cipla, CSPC Ouyi Pharmaceutical.
The montelukast drug market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Montelukast Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Montelukast Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Montelukast Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Montelukast Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Montelukast Drug Market Size & Forecast, 2018-2028
4.5.1 Montelukast Drug Market Size and Y-o-Y Growth
4.5.2 Montelukast Drug Market Absolute $ Opportunity
Chapter 5 Global Montelukast Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Montelukast Drug Market Size Forecast by Type
5.2.1 Tablets
5.2.2 Oral Granules
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Montelukast Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Montelukast Drug Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drug Store
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Montelukast Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Montelukast Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Montelukast Drug Analysis and Forecast
9.1 Introduction
9.2 North America Montelukast Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Montelukast Drug Market Size Forecast by Type
9.6.1 Tablets
9.6.2 Oral Granules
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Montelukast Drug Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drug Store
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Montelukast Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Montelukast Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Montelukast Drug Market Size Forecast by Type
10.6.1 Tablets
10.6.2 Oral Granules
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Montelukast Drug Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drug Store
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Montelukast Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Montelukast Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Montelukast Drug Market Size Forecast by Type
11.6.1 Tablets
11.6.2 Oral Granules
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Montelukast Drug Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drug Store
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Montelukast Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Montelukast Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Montelukast Drug Market Size Forecast by Type
12.6.1 Tablets
12.6.2 Oral Granules
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Montelukast Drug Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drug Store
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Montelukast Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Montelukast Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Montelukast Drug Market Size Forecast by Type
13.6.1 Tablets
13.6.2 Oral Granules
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Montelukast Drug Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drug Store
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Montelukast Drug Market: Competitive Dashboard
14.2 Global Montelukast Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck & Co.
14.3.2 Teva
14.3.3 Mylan
14.3.4 Glenmark Pharmaceuticals
14.3.5 Hikma Group
14.3.6 Sandoz
14.3.7 Torrent Pharmaceuticals
14.3.8 Lannett Company
14.3.9 Apotex
14.3.10 Dr. Reddys Laboratories
14.3.11 Aurobindo Pharma
14.3.12 Accord Healthcare
14.3.13 Hetero
14.3.14 Unimark
14.3.15 Ajanta Pharma
14.3.16 MACLEODS
14.3.17 Jubilant Pharma
14.3.18 Unichem Laboratories
14.3.19 Amneal Pharmaceuticals
14.3.20 Shanghai Anbison Lab
14.3.21 Perrigo
14.3.22 Cipla
14.3.23 CSPC Ouyi Pharmaceutical
